Efficacy of linezolid in the treatment of tuberculous meningitis: a meta-analysis-Reference-Cited by-同舟云学术

Efficacy of linezolid in the treatment of tuberculous meningitis: a meta-analysis

Published:2024-06-29 Issue:3 Volume:20 Page:1038-1042
ISSN:1734-1922
Container-title:Archives of Medical Science
language:
Short-container-title:Arch Med Sci

Author:

Liu Xiaoshu¹²,Tang Daoyan¹,Qi Min¹,He Jian-Qing¹³

Affiliation:

1. Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China

2. Department of Respiratory and Critical Care Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China

3. State Key Laboratory of Respiratory Health and Multimorbidity, China

Abstract

IntroductionTuberculous meningitis (TBM) is a severe extra-pulmonary tuberculosis with high fatality. This meta-analysis aimed to assess the impact of linezolid on TBM treatment outcomes.MethodsWe searched multiple databases for studies published up to May 18, 2024 comparing the effects of linezolid on TBM. Meta-analysis was conducted using Review Manager 5.4.ResultsOur findings indicated that linezolid may reduce treatment failure risk (RR = 0.42 (0.20, 0.89), p = 0.02) and improve temperature recovery (RR = 1.56 (1.21, 2.02), p < 0.001) in TBM patients.ConclusionsThe analysis suggests a positive association between linezolid treatment and therapeutic improvements, with no significant adverse reactions reported.

Publisher

Termedia Sp. z.o.o.

Link

https://www.archivesofmedicalscience.com/pdf-189905-112122

Reference19 articles.

1. Seddon JA, Tugume L, Solomons R, Prasad K, Bahr NC. The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res 2019; 4: 167.

2. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol 2013; 12 :999-1010.

3. World Health Organization & World Health Organization. (2010). Treatment of tuberculosis: guidelines, 4th edition. World Health Organization. https://iris.who.int/handle/10665/44165.

4. Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H. Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis. Clin Pharmacokinet 2019; 58: 1103-29.

5. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis 2010; 90: 279-92.